Payor-Provider Collaboration Driving Optimal Bispecific Therapy Strategies

EP: 1.Conditions for Administering Bispecific Therapy

EP: 2.Navigating Barriers Which Inhibit Optimal Use of Bispecifics

EP: 3.Key Decision Makers and Contributors Involved In Bispecific Administration

EP: 4.Pain Points In Bispecific Operationalization

EP: 5.Risk Evaluation and Mitigation Strategies [REMS] Program Considerations For Bispecific Therapy

EP: 6.Optimizing Bispecific Use Through EMR Utilization

EP: 7.Best Practices For Uptake and Use of Bispecific Therapy

EP: 8.Achieving Seamless Care Transitions With Patients Receiving Bispecific Therapy

EP: 9.Intro to Bispecific Therapy: Implementation Essentials for Novice Institutions

EP: 10.Key Elements In Monitoring for Potential Adverse Events with Bispecific Antibodies

EP: 11.Protocol For Urgent and Around-the-Clock Bispecific Care

EP: 12.Obstacles to Optimal Transitions of Care Between Academic and Community Settings When Utilizing Bispecific Antibodies

EP: 13.Managed Care Considerations Within Bispecific Landscape

Now Viewing

EP: 14.Payor-Provider Collaboration Driving Optimal Bispecific Therapy Strategies

EP: 15.Medication Assistance Programs Mitigating Financial Burden For Patients Receiving Bispecific Therapy

EP: 16.Bispecific Therapies: Current and Future Considerations

This is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA, CPEL; Kirollos Hanna, PharmD, BCPS, BCOP, FACCC; Sarah Rockwell, PharmD, BCOP; Melody Chang, RPh, MBA, BCOP; and Ryan Cain, PA-C.

Haumschild asks Chang to share additional best practices for providers and payers to collaborate on bispecific antibody access and approval. She stresses open communication to convey patient urgency to payers and increasing speed of approval. Keeping abreast of the latest clinical data to support indications, clearly documenting alignment with approved uses, articulating rationale based on patient history, offering educational materials on efficacy/safety/cost-effectiveness compared to alternatives, and becoming familiar with the appeals process are key. Following evidence-based guidelines can provide reassurance. Such strategies enhance the likelihood of overcoming barriers. Haumschild agrees that partnering with payers via education is key for equitable access and outcomes. Cain outlines his 1-hour patient education session reviewing risks like hospitalization for toxicity management while highlighting the high efficacy. Caregiver worries about significant cytokine release syndrome or neurotoxicity must also be addressed through reviewing safety protocols. Haumschild emphasizes shared decision-making for mutual expectations into therapy.

Video synopsis is AI-generated and reviewed by AJMC® editorial staff.